Advanced therapy medicinal products - gene therapies, cell therapies and tissue-engineered products - are the most complex and fastest-growing segment of clinical research. ATMP trials demand cold chain logistics, chain-of-custody controls and regulatory frameworks that few CROs are built to handle.
aCROss Medical is building dedicated ATMP trial capabilities across our site network in Georgia, Armenia, Israel and Uzbekistan, with Israel's world-class haematology and oncology centres providing particularly strong CAR-T and gene therapy experience.
Every Subspecialty Has Its Challenges. We Know Them All.
What Sets Us Apart in ATMP Trials
ATMP-Trained Teams
Investigators and site staff trained in chain-of-identity, chain-of-custody and ATMP-specific handling procedures.
Specialist Site Network
Academic medical centres with CAR-T, gene therapy and cell therapy experience across Israel, Georgia and Armenia.
Cold Chain & Logistics
Cryogenic storage, apheresis coordination and cell collection logistics built for complex biologics.
Enhanced Pharmacovigilance
Rigorous safety reporting and long-term follow-up (LTFU) management for ATMP-specific risks.
Regulatory Expertise
Strategy aligned with ICH E6(R2), EU ATMP Regulation (EC No 1394/2007) and local authority requirements.
aCROss was introduced to us through a mutual connection. At the outset of our trial, we had limited experience working outside the U.S. regulatory environment and needed to familiarize ourselves with the processes and operational landscape in Georgia. From the very beginning of our collaboration, it became clear that this would be more than a typical CRO partnership; it would be a true team effort, supporting us at every stage from regulatory approvals to site qualification, initiation and monitoring visits.
To us, aCROss represents professionalism, dedication, and exceptional availability. We have full confidence in their expertise and judgment in all aspects of our study, and we now look forward to continuing this successful collaboration in Phase 3.
Other Therapeutic Areas
Let's Talk About Your ATMP Study
Whether you're developing a CAR-T programme, a gene therapy for a rare disease, or a cell-based regenerative treatment - we'd love to hear about your study.
Discuss Your Study